Don Morris

4.7k total citations · 1 hit paper
91 papers, 3.3k citations indexed

About

Don Morris is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Don Morris has authored 91 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 28 papers in Genetics and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Don Morris's work include Virus-based gene therapy research (26 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Don Morris is often cited by papers focused on Virus-based gene therapy research (26 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Don Morris collaborates with scholars based in Canada, United States and Tanzania. Don Morris's co-authors include Ronald W. Davis, Daniel Shoemaker, Deval Lashkari, Peter Forsyth, Chandini M. Thirukkumaran, Nila Shah, Naiping Shen, Michael J. Kozal, Earl Hubbell and Daniel E. Meyers and has published in prestigious journals such as Nature Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Don Morris

89 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Peers

Countries citing papers authored by Don Morris

Since Specialization

Citations

This map shows the geographic impact of Don Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don Morris more than expected).

Fields of papers citing papers by Don Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don Morris. The network helps show where Don Morris may publish in the future.

Co-authorship network of co-authors of Don Morris

This figure shows the co-authorship network connecting the top 25 collaborators of Don Morris. A scholar is included among the top collaborators of Don Morris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don Morris. Don Morris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors breakdown → 2024 ·JAMA Network Open ·Sarah Cook, (unknown), Daniel E. Meyers, Igor Stukalin, (unknown), Randeep Sangha, Don Morris, Daniel Yick Chin Heng, Aliyah Pabani, Michelle L. Dean, Vishal Navani	60
2	Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade 2023 ·Clinical Lung Cancer ·Vishal Navani, Daniel E. Meyers, Yibing Ruan, Devon J. Boyne, Dylan E. O’Sullivan, (unknown), (unknown), Igor Stukalin, Daniel Yick Chin Heng, Don Morris, Darren R. Brenner, Randeep Sangha, Winson Y. Cheung, Aliyah Pabani	2
3	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials 2021 ·European Journal of Cancer ·Chun Loo Gan, Igor Stukalin, Daniel E. Meyers, Shaan Dudani, (unknown), (unknown), (unknown), (unknown), (unknown), J. Connor Wells, Aliyah Pabani, Tina Cheng, Jose Gerard Monzon, Don Morris, Naveen S. Basappa, Sumanta K. Pal, Lori Wood, Frede Donskov, Toni K. Choueiri, Daniel Y.C. Heng	32
4	P16.03 Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients 2021 ·Journal of Thoracic Oncology ·Adam Gibson, Daniel E. Meyers, Michael Dean, Igor Stukalin, Don Morris, D. Gwyn Bebb	0
5	Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer 2018 ·Cancers ·Ahmed Mostafa, Daniel E. Meyers, Chandini M. Thirukkumaran, Peter Liu, Kathy Gratton, Jason Spurrell, Qiao Shi, Satbir Thakur, Don Morris	43
6	The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer 2018 ·PLoS ONE ·Satbir Thakur, Haocheng Li, Angela Chan, (unknown), Gilbert Bigras, Don Morris, Emeka K. Enwere, Hua Yang	42
7	Surgical excision versus observation as initial management of desmoid tumors: A population based study 2018 ·European Journal of Surgical Oncology ·(unknown), (unknown), Jan‐Willem Henning, Elizabeth Kurien, Don Morris, Antoine Bouchard‐Fortier, Dan Schiller, Shannon Puloski, Michael J. Monument, Doha Itani, Lloyd A. Mack	30
8	PUMA and NF-kB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer 2017 ·PLoS ONE ·Chandini M. Thirukkumaran, (unknown), (unknown), Joanne Luider, Karen Kopciuk, Jason Spurrell, Kate Elzinga, Don Morris	25
9	PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma 2013 ·Gynecologic Oncology ·John B. McIntyre, Gregg Nelson, Prafull Ghatage, Don Morris, Máire A. Duggan, Cheng‐Han Lee, Corinne Doll, Martin Köbel	21
10	Reovirus modulates autophagy during oncolysis of multiple myeloma 2013 ·Autophagy ·Chandini M. Thirukkumaran, Zhong Qiao Shi, Joanne Luider, Karen Kopciuk, He Gao, Nizar J. Bahlis, Paola Neri, Mark Pho, Doug Stewart, Adnan Mansoor, Don Morris	43
11	MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome 2013 ·Gynecologic Oncology ·Gregg Nelson, (unknown), Sandra Lee, Guangming Han, Don Morris, Travis Ogilvie, Máire A. Duggan, Martin Köbel	40
12	Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma 2012 ·Clinical Cancer Research ·Chandini M. Thirukkumaran, Zhong Qiao Shi, Joanne Luider, Karen Kopciuk, He Gao, Nizar J. Bahlis, Paola Neri, Mark Pho, Douglas A. Stewart, Adnan Mansoor, Don Morris	60
13	Clinical trials involving the oncolytic virus, reovirus: ready for prime time? 2012 ·Expert Review of Clinical Pharmacology ·(unknown), Don Morris	24
14	CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer 2011 ·Journal of Thoracic Oncology ·(unknown), Alexander C. Klimowicz, Karen Kopciuk, Stephanie Petrillo, (unknown), Desirée Hao, Huong Muzik, (unknown), (unknown), Don Morris, Anthony M. Magliocco, D. Gwyn Bebb	60
15	Viral purging of haematological autografts: should we sneeze on the graft? 2007 ·Bone Marrow Transplantation ·Chandini M. Thirukkumaran, Jeffrey A. Russell, D. A. Stewart, Don Morris	20
16	A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma 2006 ·Sarcoma ·Don Morris, Vivien Bramwell, Robert Turcotte, A Figueredo, Martin E. Blackstein, (unknown), S. Matthews, Elizabeth A. Eisenhauer	30
17	Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience 2005 ·Bone Marrow Transplantation ·Lorraine Chow, Nizar J. Bahlis, Jeffrey A. Russell, A Chaudhry, Don Morris, Christopher Brown, Douglas A. Stewart	12
18	Groin soft tissue tumors—a challenge for local control and reconstruction: A prospective cohort analysis 2004 ·Journal of Surgical Oncology ·Lloyd A. Mack, Walley Temple, (unknown), Norman S. Schachar, Don Morris, Elizabeth Kurien	10
19	Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support 1999 ·Bone Marrow Transplantation ·Mary A. Bewick, (unknown), Michael Conlon, Robert M. Lafrenie, Don Morris, Douglas A. Stewart, Stefan Glück	23
20	Causes of higher in-hospital mortality in women than in men after acute myocardial infarction 1994 ·The American Journal of Cardiology ·J. Stephen Jenkins, Greg C. Flaker, (unknown), Leigh Ann Price, Don Morris, James Kurz, Gregory F. Petroski	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact